47 research outputs found
BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial
Background: Pruritus (itch) is a symptom commonly experienced by patients with cholestatic liver diseases such as
primary biliary cholangitis (PBC, previously referred to as primary biliary cirrhosis). Bile acids (BAs) have been proposed
as potential pruritogens in PBC. The ileal bile acid transporter (IBAT) protein expressed in the distal ileum plays a key
role in the enterohepatic circulation of BAs. Pharmacological inhibition of IBAT with GSK2330672 may reduce BA levels
in the systemic circulation and improve pruritus.
Methods: This clinical study (BAT117213 study) is sponsored by GlaxoSmithKline (GSK) with associated exploratory studies
supported by the National Institute for Health Research (NIHR). It is a phase 2a, multi-centre, randomised, double bind,
placebo controlled, cross-over trial for PBC patients with pruritus. The primary objective is to investigate the safety and
tolerability of repeat doses of GSK2330672, and explore whether GSK2330672 administration for 14 days improves pruritus
compared with placebo. The key outcomes include improvement in pruritus scores evaluated on a numerical rating scale
and other PBC symptoms in an electronic diary completed twice daily by the patients. The secondary outcomes include
the evaluation of the effect of GSK2330672 on total serum bile acid (BA) concentrations, serum markers of BA synthesis
and steady-state pharmacokinetics of ursodeoxycholic acid (UDCA).
Discussion: BAT117213 study is the first randomised controlled crossover trial of ileal bile acid transporter inhibitor, a
novel class of drug to treat pruritus in PBC. The main strengths of the trial are utility of a novel, study specific, electronic
symptom diary as patient reported outcome to measure the treatment response objectively and the crossover design
that allows estimating the treatment effect in a smaller number of patients. The outcome of this trial will inform
the trial design of future development phase of the IBAT inhibitor drug. The trial will also provide opportunity to
conduct metabonomic and gut microbiome studies as explorative and mechanistic research in patients with
cholestatic pruritus
Intraductal fully covered self-expanding metal stents in the management of post-liver transplant anastomotic strictures: a UK wide experience.
Background: Fully covered intraductal self-expanding metal stents (IDSEMS) have been well described in the management of post-liver transplant (LT) anastomotic strictures (ASs). Their antimigration waists and intraductal nature make them suited for deployment across the biliary anastomosis. Objectives: We conducted a multicentre study to analyse their use and efficacy in the management of AS. Design: This was a retrospective, multicentre observational study across nine tertiary centres in the United Kingdom. Methods: Consecutive patients who underwent endoscopic retrograde cholangiopancreatography with IDSEMS insertion were analysed retrospectively. Recorded variables included patient demographics, procedural characteristics, response to therapy and follow-up data. Results: In all, 162 patients (100 males, 62%) underwent 176 episodes of IDSEMS insertion for AS. Aetiology of liver disease in this cohort included hepatocellular carcinoma (n = 35, 22%), followed by alcohol-related liver disease (n = 29, 18%), non-alcoholic steatohepatitis (n = 20, 12%), primary biliary cholangitis (n = 15, 9%), acute liver failure (n = 13, 8%), viral hepatitis (n = 13, 8%) and autoimmune hepatitis (n = 12, 7%). Early AS occurred in 25 (15%) cases, delayed in 32 (20%) cases and late in 95 (59%) cases. Age at transplant was 54 years (range, 12-74), and stent duration was 15 weeks (range, 3 days-78 weeks). In total, 131 (81%) had complete resolution of stricture at endoscopic re-evaluation. Stricture recurrence was observed in 13 (10%) cases, with a median of 19 weeks (range, 4-88 weeks) after stent removal. At removal, there were 21 (12%) adverse events, 5 (3%) episodes of cholangitis and 2 (1%) of pancreatitis. In 11 (6%) cases, the removal wires unravelled, and 3 (2%) stents migrated. All were removed endoscopically. Conclusion: IDSEMS appears to be safe and highly efficacious in the management of post-LT AS, with low rates of AS recurrence
Complications of cholestasis
\ua9 2019Cholestasis (impairment of, or reduction in, bile flow) can both predispose to the development of chronic liver disease and result in its own specific symptoms. The severity of cholestatic symptoms (which themselves often impair quality of life) is typically independent of the severity of the underlying liver disease, the link with cholestasis therefore frequently being missed. The most characteristic symptoms of cholestasis are pruritus and fatigue, the former being the most responsive to treatment. After excluding surgically or endoscopically treatable biliary tree obstruction, the first-line treatment for cholestatic pruritus is colestyramine. Rifampicin and the oral opiate antagonist naltrexone are effective second-line treatments with a good evidence base. There is currently no licensed or recommended therapy for fatigue and the approach is largely supportive. Osteoporosis can complicate cholestatic liver disease, although the risk has previously been overstated. The highest additional cholestasis-associated risk is seen in male patients, in patients taking corticosteroids and in the most severely cholestatic patients. Patients should undergo formal bone mineral density screening, and bisphosphonate treatment is highly effective